BidaskClub lowered shares of Cara Therapeutics, Inc. (NASDAQ:CARA) from a buy rating to a hold rating in a research report sent to investors on Monday, July 31st.
A number of other equities analysts also recently commented on the stock. Vetr upgraded shares of Cara Therapeutics from a hold rating to a strong-buy rating and set a $19.90 target price for the company in a report on Friday, April 14th. Raymond James Financial, Inc. reiterated a market perform rating and issued a $30.00 target price on shares of Cara Therapeutics in a report on Friday, April 28th. Cantor Fitzgerald reiterated an overweight rating and issued a $29.00 target price on shares of Cara Therapeutics in a report on Friday, May 19th. Scotiabank boosted their target price on shares of Cara Therapeutics from $33.00 to $34.00 and gave the stock an outperform rating in a report on Monday, May 15th. Finally, Canaccord Genuity reiterated a buy rating and issued a $25.00 target price on shares of Cara Therapeutics in a report on Wednesday, May 17th. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $25.18.
Cara Therapeutics (CARA) opened at 13.96 on Monday. The stock’s 50 day moving average is $16.04 and its 200 day moving average is $16.39. Cara Therapeutics has a one year low of $5.27 and a one year high of $28.50. The company’s market capitalization is $454.83 million.
Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.32. During the same quarter in the previous year, the business earned ($0.48) earnings per share. The firm’s quarterly revenue was down 100.0% compared to the same quarter last year. On average, analysts anticipate that Cara Therapeutics will post ($1.78) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Cara Therapeutics, Inc. (NASDAQ:CARA) Downgraded to Hold at BidaskClub” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/08/12/cara-therapeutics-inc-nasdaqcara-downgraded-by-bidaskclub-to-hold-updated.html.
In related news, CEO Derek T. Chalmers sold 25,000 shares of the stock in a transaction on Friday, July 14th. The stock was sold at an average price of $15.05, for a total value of $376,250.00. Following the completion of the transaction, the chief executive officer now directly owns 1,107,292 shares of the company’s stock, valued at approximately $16,664,744.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Frederique Ph.D. Menzaghi sold 3,000 shares of the stock in a transaction on Friday, July 14th. The shares were sold at an average price of $15.00, for a total value of $45,000.00. Following the completion of the transaction, the vice president now directly owns 120,000 shares of the company’s stock, valued at $1,800,000. The disclosure for this sale can be found here. Insiders have sold a total of 278,000 shares of company stock worth $6,888,750 in the last quarter. Insiders own 7.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of CARA. Quantbot Technologies LP purchased a new position in Cara Therapeutics during the first quarter valued at approximately $124,000. Legal & General Group Plc increased its position in Cara Therapeutics by 10.4% in the second quarter. Legal & General Group Plc now owns 7,167 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 678 shares in the last quarter. UBS Group AG increased its position in Cara Therapeutics by 16.9% in the first quarter. UBS Group AG now owns 10,544 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 1,528 shares in the last quarter. Capital Fund Management S.A. purchased a new position in Cara Therapeutics during the second quarter valued at approximately $171,000. Finally, Cambridge Investment Research Advisors Inc. increased its position in Cara Therapeutics by 0.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 11,824 shares of the biopharmaceutical company’s stock valued at $217,000 after buying an additional 60 shares in the last quarter. 52.75% of the stock is owned by hedge funds and other institutional investors.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
What are top analysts saying about Cara Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cara Therapeutics Inc. and related companies.